Compare Las Vegas Sands Corp. (LVS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Medpace Holdings Inc — how do they compare? Las Vegas Sands Corp. trades at $36.2 (market cap $23.38B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Medpace Holdings Inc for 14 Days on average.
| LVS | MEDP | |
|---|---|---|
Market Cap | $23.38B | $16.82B |
Volume | 6,994,661 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $630.19 |
52-Week Low | $35.81 | $393.42 |
Typical Hold Time | 72 Days | 14 Days |
Enterprise Value | $35.27B | $16.44B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.17, up 1.01% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 12.59% net margin and 134.29% ROE, supported by $13.02B in 2025 revenue. Analysts are bullish with a $59.78 consensus target, but the stock faces headwinds from high debt levels and a recent Q2 2026 earnings miss.
The outlook for LVS is mixed; solid fundamentals and analyst support suggest upside, but technical weakness and leverage risks warrant caution. Investment opportunity lies in valuation discount versus peers, while risks include debt servicing and Macao regulatory exposure.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
